Le Lézard
Classified in: Health, Science and technology

Change in the Number of Shares and Votes in BioInvent International AB

LUND, SE / ACCESSWIRE / January 31, 2023 / BioInvent International (STO:BINV)

Lund, Sweden, January 31, 2023 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per January 31, 2023 amounts to 65,804,362 shares, corresponding to an equal number of votes.

The increase in the number of shares and votes results from the directed issue of USD 3 million (approximately SEK 31 million) to Leukemia & Lymphoma Society's Therapy Acceleration Program® (LLS TAP) by issuance of 836,478 shares, announced on January 17, 2023 in connection with BioInvent entered into a partnership with LLS TAP.

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.

For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
[email protected]

BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50

This information is information that BioInvent International is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-01-31 10:00 CET.


Change in the number of shares and votes in BioInvent International AB

SOURCE: BioInvent International

View source version on accesswire.com:

These press releases may also interest you

at 01:47
Recently, Meishe Co., Ltd. released Web Editor version 3.0, with three major upgrades aimed at improving production efficiency, displaying strength in the production of digital human content, supporting local-cloud mix editing, etc. It is a web video...

at 01:25
BTCEX, one of the major cryptocurrency exchanges, has announced a partnering program with W Economy TV, a leading cryptocurrency consulting brand. The partnership aims to share policies and information and create meaningful synergy for customized...

at 01:23
On March 10, 2023, Pylon Technologies Co., Ltd. ("Pylontech") (Stock No. 688063) announced that its marine lithium-ion battery system received JET certificate in Japan. This certificate, issued on the basis of JIS C 8715-2: 2019, is another sign of...

at 01:05
Blackline Safety Corp. ("Blackline" or the "Company") a global leader in connected safety technology with a hardware-enabled software-as-a-service (HeSaaS) business model held its annual and special meeting (the "Meeting") of shareholders on March...

at 01:05
Canva, the world's only all-in-one visual communication platform, today announced a new suite of brand management features and AI-powered design tools, built to help teams and organizations of all shapes and sizes to communicate visually and produce...

at 01:00
Trident University International, a member of the American InterContinental University System (Trident), was honored to present at the annual Professional Development Symposium of The Council...

News published on 31 january 2023 at 04:27 and distributed by: